Self-amplifying mRNA vaccine shows stronger immune responses 180+ days after COVID shot

Key Findings

🎯 DNA-guided method creates better-targeted cancer treatments

• Researchers developed a DNA-tethering system to rapidly attach commercial antibodies to lipid nanoparticles for T cell gene delivery

• Bispecific formulations (targeting two receptors simultaneously) improved T cell targeting and mRNA transfection compared to single-targeted versions

• The approach enables high-throughput screening of antibody combinations for diseases from B cell lymphomas to autoimmune conditions

🔬 Engineered enzyme eliminates 99% of problematic RNA byproducts

• Scientists used directed evolution to modify T7 RNA polymerase, the enzyme that makes mRNA for therapeutics

• The engineered version with double mutations (M183E + I210V) reduced dangerous double-stranded RNA contamination by over 99%

• Double-stranded RNA triggers strong immune responses that can derail mRNA therapies, making this a critical manufacturing breakthrough

📊 Lipid components persist in tissues weeks after mRNA injection

• Researchers tracked the synthetic lipid ALC-0315 (used in COVID vaccines) in mice for weeks after injection

• While the lipid cleared rapidly from blood, it remained in liver and spleen tissue for several weeks

• Spike protein expression peaked at 6 hours and was highest in liver, followed by spleen, heart, kidney and lung

🎯 Water-based nanoparticles target organs beyond the liver

• Scientists developed ethanol-free, water-based lipid nanoparticles that avoid traditional PEG components

• These particles preferentially delivered genes to tissues outside the liver, unlike conventional formulations that mainly target liver cells

• The system efficiently delivered CRISPR components and transfected primary human immune cells

🔬 New analysis method reveals nanoparticle structure at sub-10nm scale

• Researchers combined flow field-flow fractionation with X-ray and neutron scattering to map lipid nanoparticle structure

• The technique revealed a 2-3 nm polar shell surrounding an internal core-shell architecture in solid-liquid particles

• The method accurately captures primary particles down to ~5 nm, while light scattering mainly detects loose aggregates

📈 Vertical microfluidic system scales nanoparticle production 7-fold

• A five-layer microfluidic device achieved 0.96 L per hour production rate while maintaining particle quality

• Nanoparticles consistently measured 100-150 nm with low variability and >96% drug encapsulation efficiency

• An 80-cartridge platform could theoretically reach 80 L per hour, approaching industrial manufacturing scales